DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Teduglutide
Teduglutide
The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
Teduglutide
Gattex Teduglutide Rdna Origin
Teduglutide for Treating Short Bowel Syndrome
Membrane-Tethered Ligands Are Effective Probes for Exploring Class B1 G Protein-Coupled Receptor Function
WO 2018/142363 Al 09 August 2018 (09.08.2018) W !P O PCT
Identification and Characterization of the Glucagon- Like Peptide-2 Hormonal System in Ruminants
WO 2019/069274 Al 11 April 2019 (11.04.2019) W 1P O PCT
ADOCIA Corporate Presentation
Presentation of Several Zealand Peptide Therapeutics at the Th American Diabetes Association’S (ADA) 74 Scientific Sessions
BCBSM Clinical Drug List (Formulary)
GATTEX (Teduglutide) RATIONALE for INCLUSION in PA PROGRAM
Press Release
Lists of Medicinal Products for Rare Diseases in Europe*
Annual Report 2016
Injectable Medication Hcpcs/Dofr Crosswalk
Stembook 2018.Pdf
Glucagon-Like Peptide-1 Receptor Agonists Are Not Associated with Retinal Adverse Events in the FDA Adverse Event Reporting System
Top View
Guidance for Industry- Synthetic Peptides
Towards a Peptide Implant : Analytics , Dry Heat Behavior and Functional Characterization
Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs
Self-Administered Specialty Drug List
Discovery, Characterization, and Clinical Development of the Glucagon-Like Peptides
Minutes of PRAC Meeting on 12-15 March 2019 for Publication
Specialty Formulary
Eappendix Table 1. Drug Classifications I
Teduglutide (Gattex )
Press Release
Press Release
Zp7570: a Novel Glp-1/Glp-2 Dual Acting Peptide with Potential As The
Reimbursement Criteria for Frequently Requested Drugs
The Effects of Ph and Excipients on Exenatide Stability in Solution
NH Medicaid Top 25 Drugs by Cost Page 1 of 5 MAC 09/18/18 State
Bindex 559..578
GLP-1 and Intestinal Diseases
Teduglutide (Gattex®) Increases Small Intestinal Mass in Preclinical Study • 39 Amino Acids • 33 Amino Acids
203441Orig1s000
PRESS RELEASE Adocia Announces Expanded Biochaperone® Product
Press Release
Biologics Monographs 1–Peptides Expert Committee (BIO1 EC) November 4–5, 2015 USP–U.S
WHO Prequalification of Medicines
Evaluating the Need for an Orphan Drug Act in India by Comparing It with the US Orphan
Quarterly Securities Report
PRESS RELEASE Number of Shares and Voting Rights of ADOCIA As Of
The Role of Teduglutide in Weaning Parenteral
Clinical Pharmacy Forum March April Newsletter 2014 Issue 2
HTL'023 | DUAL GLP-2/GLP-1 Agonist
Prediction and Validation of Immunogenicity and Tolerance to Generic Peptides & Impurities HTREG IGGC-289 Anne S
Andas for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Rdna Origin
A Unique Hormonal Recognition Feature of the Human Glucagon-Like Peptide-2 Receptor
Revestive : EPAR
Self-Administered Medications List
Pdl 7/1/2014
P&T Summary 3Q2019
GATTEX (Teduglutide [Rdna Origin]), for Injection, for Subcutaneous Use and Management
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Prior Authorization — Premium
Paragraph IV Patent Certifications (PPIV)
Immunogenicity 2021
[Docket No. FDA-2017-D-5767] Abbreviated New Drug
The Birth of an Orphan Biosimilar Market Orphans Should Live Alone
Glucagonlike Peptide 2 Analogue Teduglutide Stimulation of Proliferation but Reduction of Differentiation in Human Caco-2 Intestinal Epithelial Cells
The Global Leader in Rare Diseases We Are Proud to Be the Global Leader in Treating Rare Diseases
ESPEN Guidelines on Chronic Intestinal Failure in Adults
Glepaglutide for SBS: Phase 3 Program Ongoing
WO 2010/063124 Al
Cloning, Fed-Batch Expression and Purification of a Novel Anti
Title: the Enteric Nervous System and Its Emerging Role As a Therapeutic Target
Complex Polypeptides: Are Scientific Regulatory Considerations More Aligned to Generics Or Biosimilars?
Russia | List of Pediatric Rare Diseases and Orphan Drugs
Zealand Pharma A/S Page 1 Forward-Looking Statements